Drug Discovery World
JANUARY 5, 2024
This study offers participants a new hope for arresting relentless disability worsening and a potentially durable, treatment-free remission,” said Bruce Cree, Clinical Research Director and Professor of Clinical Neurology at the University of California, San Francisco, CA.
Drug Discovery World
FEBRUARY 6, 2024
The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The study will assess the therapy administered alone or in combination with immune checkpoint inhibitor pembrolizumab.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MAY 2, 2024
Hailed as a revolution in the treatment of many diseases, cell and gene therapy (CGT) is the fastest growing area of therapeutics. Perhaps most significantly, Casgevy (or exa-cel) from Vertex Pharmaceuticals and CRISPR Therapeutics, was approved to treat sickle cell disease and became the first gene therapy that uses CRISPR gene editing.
Vial
DECEMBER 11, 2023
In the decades since its identification in 1989, advances in clinical research for new Hepatitis C therapies and the introduction of direct-acting antiviral agents (DAAs) have led to viral eradication in more than 98% of patients, resulting in HCV crossing from manageable to being the first curable , chronic viral infection.
SCIENMAG: Medicine & Health
JULY 21, 2023
In a pilot study of 165 people, Mayo Clinic researchers looked at the effectiveness of two different approaches to weight loss: a standard lifestyle intervention and individualized therapy. The standard lifestyle intervention included a reduced diet, exercise and behavior therapy. ROCHESTER, Minn. —
PPD
JUNE 10, 2024
We are thrilled to announce that the PPD clinical research business of Thermo Fisher Scientific is getting a brand refresh! Our new visual identity will align more closely with Thermo Fisher’s style, while still retaining elements unique to our PPD clinical research business. What’s changing? Ready to unlock efficiencies?
Drug Discovery World
FEBRUARY 19, 2024
The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options.”
Expert insights. Personalized for you.
313 
Let's personalize your content